Trodelvy in India: A Sourcing Guide for Hospitals Treating Triple-Negative Breast Cancer

Why Trodelvy Is Important for TNBC Treatment

Buy Trodelvy in India — Licensed Importer & Distributor | Indian Pharma Network

Trodelvy in India has become an increasingly requested medicine among oncology centres for treating patients with triple-negative breast cancer (TNBC) and HR+/HER2- metastatic breast cancer. As hospital demand for this antibody-drug conjugate (ADC) grows across India, procurement teams and pharmacy directors are asking more practical, supply-focused questions — less about clinical efficacy (which is well established in oncology literature) and more about how to source Trodelvy reliably, verify authenticity, understand prices, and manage the complex logistics inherent in supplying a temperature-sensitive biologic medicine to Indian institutions.

This guide addresses those real-world sourcing questions from a licensed distributor’s perspective.

What Is Trodelvy? Clinical Context & Market Status in India:

Trodelvy (Sacituzumab Govitecan-hziy) is an antibody-drug conjugate (ADC) — a class of targeted cancer therapies combining a monoclonal antibody with a cytotoxic payload. This medicine is used in the treatment of certain breast cancers, particularly triple-negative breast cancer (TNBC) and HR+/HER2- metastatic breast cancer, according to the FDA-approved prescribing information and regulatory guidance adopted in India’s oncology practice.

Key Clinical Information:

• Mechanism: ADC combining anti-TROP-2 antibody with topoisomerase I inhibitor
• Indication: Metastatic triple-negative breast cancer (mTNBC); increasingly used for early breast cancer in specialized Indian oncology centres
• Clinical Trial Reference: ASCENT trial (published New England Journal of Medicine, 2019) demonstrated median overall survival benefit in mTNBC populations
• Manufacturing: Gilead Sciences (licensor) / Immunomedics formulation; distributed globally under strict regulatory oversight

Important: The decision to prescribe Trodelvy, along with dosing regimens and treatment monitoring protocols, rests entirely with the treating oncologist based on current approved labeling and individual patient assessment. This article does not provide clinical or treatment guidance and should not be used as a substitute for the approved prescribing information or consultation with a qualified medical oncologist.

Why Sourcing Trodelvy in India Requires Specialized Distributor Networks?

Antibody-drug conjugates like Trodelvy occupy a unique position in India’s pharmaceutical supply ecosystem. Unlike conventional oncology tablets or even many small-molecule targeted therapies, they are complex biologic products requiring:

• Unbroken cold chain handling from manufacturer through hospital administration

• Batch-level traceability documented at every transfer point

• Import and regulatory compliance aligned with India’s pharmaceutical importation rules

• Verified authenticity protocols to prevent counterfeited or degraded product

• Specialized storage infrastructure not available through general pharmaceutical wholesalers

For Indian hospital procurement teams accustomed to sourcing through broad wholesaler networks, this represents a meaningful shift in supplier relationships and operational requirements.

Four Key Factors Distinguishing ADC Sourcing From Conventional Oncology Medicines:

Temperature Sensitivity & Cold Chain Mandates

Trodelvy requires consistent refrigerated storage at 2°C to 8°C from the point of manufacture through to bedside administration. Any temperature excursion — even brief exposure to ambient temperature — can compromise the medicine’s stability, sterility, and therapeutic efficacy. This is fundamentally different from room-temperature oncology tablets.

Batch-Specific Documentation & Lot Traceability

Biologic manufacturing introduces inherent batch-to-batch variability. Each lot of Trodelvy must be tracked with complete documentation — batch number, manufacturing date, expiry, certificate of analysis (CoA), and sterility certification — from origin through end use. This supports both regulatory compliance and rapid response if any batch-level safety signal emerges.

Limited Supplier Networks in India

Unlike aspirin or standard chemotherapy tablets available through hundreds of wholesale channels, Trodelvy in India is sourced through a small number of licensed specialty distributors with:

• Import licenses for biologics
• Cold chain infrastructure
• Regulatory compliance documentation
• Direct relationships with international manufacturers

 Import Documentation & Customs Compliance

Trodelvy imported into India requires complete import licenses, customs declarations, and in-country distribution authorization. This documentation must accompany every shipment and be available for hospital audit.

What Hospitals & Pharmacies Should Verify When Sourcing Trodelvy in India

Before accepting delivery of Trodelvy or any comparable specialty oncology biologic, Indian procurement teams should verify the following checklist:

Pre-Delivery Verification Checklist:

• Batch number and expiry date clearly printed on vial labels, matching the accompanying certificate of analysis
• Cold chain compliance documentation — temperature logs for transit, arriving within specified 2°C–8°C range
• Manufacturer packaging authenticity — consistent packaging appearance, holographic security elements, and labeling matching known authentic samples from official manufacturer databases
• Complete import and supply paperwork — import licenses, customs clearance, pharmacy council registration, particularly important for institutional or bulk procurement
• Vial integrity on arrival — visible inspection for signs of temperature excursion (condensation inside packaging, compromised seals, particulate matter, discoloration)
• Certificate of Analysis — sterility testing, endotoxin testing, identity confirmation from the manufacturing source
• Distributor credentials — verification that the distributor holds valid import licenses and has regulatory standing with India’s Central Drugs Standard Control Organization (CDSCO)

This diligence protects both patient safety and the hospital’s regulatory position, particularly given the high cost and clinical sensitivity of ADC therapies.

Triple-Negative Breast Cancer in India: Clinical Burden & Treatment Evolution

Triple-negative breast cancer (TNBC) represents approximately 10–20% of all breast cancer diagnoses in India (based on institutional oncology registry data), with a notably aggressive clinical course and poorer prognosis compared to hormone receptor-positive or HER2-positive subtypes.

Historical Treatment Limitations in India:

• Limited access to targeted therapies designed specifically for TNBC
• Reliance on conventional chemotherapy regimens (anthracyclines, taxanes)
• Fewer treatment options at metastatic progression
• Significant unmet clinical need in Indian oncology practice

Recent Shift — Availability of Newer ADCs:

The introduction of antibody-drug conjugates like Trodelvy, alongside checkpoint inhibitors and other targeted approaches, has expanded Indian oncology centres’ therapeutic arsenal for TNBC. This has created growing demand among hospital procurement teams to source and manage these specialized biologics reliably.

Clinical Note: As Indian oncology centres increasingly adopt these medicines, the ability to source Trodelvy consistently, verify authenticity, and maintain cold chain compliance has become a core competency for pharmacy directors and procurement specialists.

Trodelvy vs. Conventional Oncology Medicines: Supply Chain Comparison Table

Trodelvy Pricing in India: Factors Affecting Cost & Availability

Hospital procurement teams often ask about Trodelvy pricing in India. Several factors influence cost:

Drivers of Trodelvy Pricing in the Indian Market:

• International acquisition cost — Pricing from the manufacturer or authorized international distributor
• Import duties & regulatory compliance — Customs duties, CDSCO registration fees
• Cold chain logistics — Specialized refrigerated transport from port to distributor to hospital
• Distributor margin — Specialty biologic margins typically higher than conventional pharmaceuticals, reflecting infrastructure costs
• Batch size & regularity — Bulk orders may offer volume advantages
• Currency fluctuation — Since Trodelvy is typically priced in USD internationally, INR exchange rates affect landed cost

Transparency Note: Trodelvy is a high-cost specialty medicine. Hospitals should expect high pricing, though final pricing depends on current sourcing rates and volume commitments. Procurement teams should request formal quotations from licensed distributors rather than relying on approximate estimates.

Working With a Specialty Distributor for Oncology Biologics:
Due to the complexity of sourcing imported oncology

medicines, many Indian hospitals and cancer centres are choosing to work with a single specialized supplier instead of managing multiple suppliers for different medicines. This makes the process easier by providing one point of contact for documentation, maintaining proper storage and temperature conditions for sensitive medicines, and ensuring that all medicines are genuine and safely supplied. It also reduces the time and effort required for hospitals to manage multiple vendors.

How Indian Pharma Network Supplies Trodelvy:

Indian Pharma Network (IPN) is a licensed specialty medicine supplier in Delhi supplying genuine Trodelvy (Sacituzumab Govitecan) to hospitals, oncology centres, and pharmacies across India. As a supplier focused on specialty and imported medicines, Indian Pharma Network (IPN) maintains certified cold chain infrastructure from procurement through last-mile hospital delivery, along with complete batch documentation for every shipment. Hospitals sourcing Trodelvy alongside other oncology biologics — including Enhertu (Trastuzumab Deruxtecan) for HER2-positive breast cancer — often find it more efficient to consolidate procurement through a single specialty oncology distributor.

Disclaimer:

This article is intended for informational and pharmaceutical procurement purposes only and does not constitute medical, clinical, or treatment advice. All clinical decisions, including drug selection, dosing, treatment duration, and patient monitoring, should be made by a qualified healthcare professional (oncologist, medical team) in accordance with the approved prescribing information, current clinical guidelines, and individual patient assessment.

Indian Pharma Network is a licensed pharmaceutical importer and specialty medicine distributor in India. We supply genuine medicines to institutional customers and do not provide clinical guidance, medical advice, or treatment recommendations.

For medical questions, please consult your oncologist or treating physician. For procurement and sourcing inquiries,

• Contact Indian Pharma Network at
• info@indianpharmanetwork.in.